Soligenix CEO to Present at H.C. Wainwright Global Investment Conference
Soligenix Inc.'s CEO presentation at the upcoming investment conference highlights the company's progress in developing treatments for rare diseases and vaccines for public health threats, signaling important advancements for investors and patients.
Soligenix Inc. (NASDAQ: SNGX) announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025. The on-demand presentation will be available beginning September 5 at 7 a.m. ET through the conference platform, with Soligenix management also participating in one-on-one meetings during the event.
The significance of this presentation lies in Soligenix's position as a late-stage biopharmaceutical company focused on developing treatments for rare diseases with unmet medical needs. The company's Specialized BioTherapeutics business segment is advancing HyBryte™ (SGX301) toward potential commercialization as a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.
Additional development programs in this segment include expansion of synthetic hypericin (SGX302) into psoriasis treatment, first-in-class innate defense regulator technology dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 for Behcet's Disease. The company's Public Health Solutions business segment includes vaccine development programs for ricin toxin, filoviruses such as Marburg and Ebola, and CiVax™ for COVID-19 prevention.
Investors can access the latest news and updates relating to SNGX through the company's newsroom at https://ibn.fm/SNGX. The company's vaccine programs incorporate proprietary heat stabilization platform technology known as ThermoVax®, with development supported by government grant and contract funding from the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.
The presentation at this major investment conference provides an opportunity for Soligenix to showcase its progress in addressing significant medical challenges, particularly in rare disease treatment and public health vaccine development. The company's dual focus on specialized therapeutics and public health solutions represents a strategic approach to addressing both niche medical markets and broader global health concerns.